Spiromustine and intracarotid artery cisplatin in the treatment of glioblastoma multiforme.
Glioblastoma multiforme is a highly malignant and rapid-growing primary brain tumor. It constitutes one-fourth of all intracranial tumors and about half of all gliomas. Survival rate following conventional treatment is only 12 to 18 months. At the National Institutes of Health, two promising therapies are currently undergoing clinical trials. Spirohydantoin mustard (spiromustine) is a combination of a nitrogen mustard and a derivative of phenytoin, an anticonvulsant drug that rapidly penetrates the blood-brain barrier and localizes in brain tumors. Intracarotid administration of cis-diamminedichloroplatinum (cisplatin) increases drug delivery to the tumor and, through hemodialysis, systemic exposure is reduced. Nursing management of patients receiving these two agents requires precise planning and implementation of an individualized plan of care to ensure a successful chemotherapeutic regimen.
D001932:Brain Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology / Q000628:therapy; D002339:Carotid Arteries; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005909:Glioblastoma / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D006827:Hydantoins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007261:Infusions, Intra-Arterial; D009316:National Institutes of Health (U.S.); D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009859:Oncology Nursing; D014481:United States
D006827:Hydantoins; D009588:Nitrogen Mustard Compounds; C015511:spiromustine; D002945:Cisplatin